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Venous thromboembolism (VTE) is a spectrum of diseases that includes deep vein throm-
bosis (DVT) and pulmonary embolism (PE). Anticoagulant treatment is the mainstay of 
therapy for VTE. Unfractionated heparin (UFH) or low molecular weight heparin (LMWH) 
followed by vitamin K antagonists have been the treatment of choice for most patients 
with VTE, with the aim to prevent thrombus extension or embolization and recurrent VTE. 
Fondaparinux, a selective, indirect, parenteral factor Xa inhibitor, is now also approved 
for the initial treatment of VTE and represents an important alternative to UFH or LMWH. 
Secondary prevention of VTE with vitamin K antagonists is usually prescribed for a mini-
mum of three months, with the duration of treatment based on the presence or absence 
of major identifiable risk factors for the index event. Patients with permanent risk factors 
or patients with recurrent DVT or PE require life long secondary prevention. Over the last 
years, new oral anticoagulant agents have been developed and are now undergoing ex-
tensive clinical evaluation in several settings, including the treatment of VTE. New oral 
anticoagulants include selective, direct thrombin inhibitors, such as dabigatran etexilate, 
and selective, direct factor Xa inhibitos, such as rivaroxaban, apixaban or edoxaban. All 
these drugs are admistered at fixed daily doses and do not require laboratory monitoring. 
The positive results of the first completed clinical trials suggest that a new era in the man-
agement of VTE is about to begin.
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STATE OF THE ART IN THE TREATMENT OF VENOUS 
THROMBOEMBOLISM
    Deep vein thrombosis  (DVT) and pulmonary embolism 
(PE) are important pathologies that affect apparently healthy 
individuals as well as medical or surgical patients. Therapeu-
tic objectives are essentially the prevention of thrombus 
extension and embolization, and the prevention of recurrent 
episodes of venous thromboembolism (VTE) to reduce the 
risk of fatal pulmonary emboli. Despite the availability of 
different treatment strategies, the large majority of  patients 
commonly receive a similar therapeutic approach, and the 
choice of the treatment is eventually influenced by the se-
verity of the presentation of the disease. Anticoagulation 
is the main therapy for acute VTE and the evidence for 
the need for anticoagulation in these patients is based on 
the results of clinical studies performed more than 40 years 
ago [1]. Patients need to start treatment as soon as the diag-
nosis is confirmed by objective testing, and because anti-
coagulant drugs with a rapid onset of action are needed 
in this phase, three parenteral therapeutic options are cur-
rently available for  initial treatment: unfractionated heparin 
(UFH), low-molecular-weight heparin (LMWH), and fonda-
parinux [2]. Fondaparinux is a synthetic pentasaccharide that 
inhibits factor Xa indirectly by binding to antithrombin with 
high affinity and was recommended for the first time in 
the 8
th edition of the American College of Chest Physicians 
(ACCP) Guidelines on Antithrombotic and Thrombolytic 
Therapy, which is the most recent and was published in 
2008 [2]. This recommendation was based on the results 
of the MATISSE studies [3, 4]. In the MATISSE DVT study 
[3], 2205 patients with DVT were treated with a once daily 
subcutaneous dose of fondaparinux (7.5 mg for patients 
weighting 50 to 100 kg, 5.0 mg for patients weighting less 
than 50 kg and 10.0 mg for patients weighting more than 
100 kg) or with a twice daily subcutaneous dose of enoxaparin 
(1 mg/kg) for at least five days.  There were no differences 
in the incidence of recurrent VTE at 3 months (3.9% vs 
4.1%), major bleeding while on treatment (1.1% vs 1.2%), 
and mortality at 3 months (3.8% vs 3.0%). In the MATISSE 
PE study [4], 2213 patients with acute PE were randomly 
allocated to treatment with subcutaneous fondaparinux or Korean J Hematol 2010;45:8-13
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intravenous UHF. Recurrence of VTE at 3 months (3.8% 
vs 5.0%) and major bleeding while on treatment (1.3% vs 
1.1%) were again similar between the two groups.
  In selected cases, more aggressive treatment strategies are 
required. There is widespread agreement that patients with 
PE resulting in cardiogenic shock initially treated with 
thrombolysis plus anticoagulation have better short- and 
long-term clinical outcomes than those who receive anti-
coagulation alone [5]. More recently, some authors have 
proposed that thrombolysis should be administered to pa-
tients with normal blood pressure (and no contraindications) 
when clinical or echocardiographic evidence of right ven-
tricular dysfunction is present. In the most recent ACCP 
guidelines [2], the use of thrombolytic therapy, which was 
previously recommended for hemodynamically unstable pa-
tients (massive PE) only, is now also suggested for selected 
high-risk patients without hemodynamic instability and with 
a low risk of bleeding, with a grade 2B recommendation. 
However, this remains a controversial issue, and the con-
troversy is likely to remain at least until the results of an 
ongoing European trial, in which 1,000 PE patients with 
preserved systolic blood pressure, elevated troponin levels, 
and right ventricular enlargement on echocardiography are 
randomised to thrombolytic therapy (tenecteplase plus hep-
arin) versus heparin alone, will become available. Other 
guidelines, such as those of the European Society of Cardiol-
ogy, currently do not recommend routine use of thrombolysis 
in non-high-risk patients [6].
  As soon as possible after the diagnosis of VTE, most patients 
are also started on oral anticoagulant treatment with vitamin 
K antagonists for the long-term secondary prevention of 
the disease. Because of their slow onset of action, and because 
of their potential to paradoxically increase the prothrombotic 
state of the patient by also inhibiting endogenous anti-
coagulants such as protein C, vitamin K antagonists can not 
be used as the only treatment strategy during the acute 
phase of disease and thus require initial association with 
parenteral anticoagulants for a minimum of 5 days. After 
this period, oral anticoagulant therapy alone is continued 
until its benefits (reduction of recurrent VTE) no longer 
clearly outweigh its risks (increase in bleeding). The risk 
of recurrence after stopping therapy is largely determined 
by two factors: whether the acute episode of VTE has been 
effectively treated; and the patient intrinsic risk of having 
a new episode of VTE. Therefore, guidelines suggest to treat 
VTE for at least 3 months if transient risk factors are identified 
and to consider long-term treatment for patients with un-
provoked proximal VTE and no risk factors for bleeding, 
in whom good quality anticoagulant monitoring is achievable 
[2]. When the risk to benefit ratio remains uncertain, patient 
preference to continue or to stop treatment should also be 
taken into account. VTE is defined unprovoked if cancer 
or a reversible provoking risk factor is not present. Reversible 
provoking factors include major risk factors such as surgery, 
hospitalization, or plaster cast immobilization, if within 1 
month; and minor risk factors such as surgery, hospital-
ization, or plaster cast immobilization, if they have occurred 
1 to 3 months before the diagnosis of VTE, and estrogen 
therapy, pregnancy, or prolonged travel (i.e. more than 8 
hours). The greater is the impact of the provoking reversible 
risk factor (e.g., recent major surgery) on the risk of VTE, 
the lower is the expected risk of recurrence after stopping 
anticoagulant therapy. Of interest, in the most recent version 
of the ACCP guidelines, the presence of thrombophilia is 
no longer considered for the risk stratification of the patients.
  For the secondary prevention of VTE in patients with 
active cancer, the use of LMWH for the first 3 to 6 months 
is now preferred over the use of vitamin K antagonists [2]. 
This recommendation is based on the results of three studies 
that selectively enrolled a total of 1,029 patients with VTE 
in association with active cancer and that found that, com-
pared to oral anticoagulant therapy with vitamin K antago-
nists, 3 months or 6 months of therapeutic-dose LMWH 
was associated with less recurrent VTE in one study and 
less bleeding in another study (relative risk for the three 
studies: recurrent VTE, 0.56; 95% CI, 0.38-0.82; major bleed-
ing, 1.01; 95% CI, 0.62-1.64; mortality, 0.92; 95% CI, 0.78- 
1.10) [7-9]. LMWH is usually administered at full therapeutic 
dose for the first month and then reduced at approximately 
75% of the initial dose thereafter.  
NEW STRAEGIES TO INDIVIDUALIZE THE 
DURATION OF SECONDARY PREVENTION
  There is a trend toward a more extended duration (poten-
tially life-long) of secondary prevention for a large proportion 
of patients with a first episode of VTE, namely those with 
an unprovoked proximal DVT or PE who have a low risk 
of bleeding and those with a permanent risk factor such 
as cancer [2]. Indeed, given the high rate of VTE events 
still defined as unprovoked, which ranges between 26% and 
47% [10], this recommendation has an enormous potential 
impact on the long-term management of patients with VTE 
and on related costs. To overcome this problem, there is 
an increasing interest in the use of clinical prognostic factors 
to assist clinicians in individualizing the optimal duration 
of secondary prevention of unprovoked VTE. These include 
the measurements of D-dimer and of residual venous ob-
struction at ultrasound. These strategies, although still not 
widely accepted, are now supported by the results of random-
ized clinical trials and of large cohort studies [11-16]. In 
the PROLONG study [11], patients with unprovoked VTE 
underwent D-dimer testing 1 month after oral anticoagulant 
treatment discontinuation. Patients with a normal D-dimer 
level did not resume anticoagulation, whereas those with 
an abnormal D-dimer level were randomly assigned either 
to resume or to discontinue treatment. The D-dimer assay 
was abnormal in 36.7% of patients. The rate of recurrences 
was 15.0% among the 120 patients who stopped anti-
coagulation as compared with 2.9% among the 103 patients 
who resumed anticoagulation, for an adjusted hazard ratio 
of 4.26 (95% confidence interval, 1.23-14.6). VTE recurred 
in 6.2% of patients with a normal D-dimer level. Because Korean J Hematol 2010;45:8-13.
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Fig. 1. Mechanism of action of anti-
thrombotic agents in the coagulation 
pathways. Direct factor Xa (FXa) inhi-
bitors (e.g. Rivaroxaban, Apixaban) are 
able to inhibit in a selective and re-
versible manner the active site of both 
free and prothrombinase-bound FXa. 
Dabigatran etexilate is an univalent 
direct thrombin inhibitor that binds 
exclusively to the active site of throm-
bin (FIIa) to inactivate fibrin-bound th-
rombin. Binding with antithrombin (AT)
respectively, the unfractionated hepa-
rin (UFH) inhibits factors XIa, IXa, Xa, 
and IIa, where as the low-molecular- 
eight heparin (LMWH) inhibits FXa and 
FIIa. Fondaparinux is a synthetic pen-
tasaccharide that inhibits FXa only 
indirectly by binding to AT with high 
affinity.
D-dimer levels may increase over time and a single normal 
D-dimer may be inadequate to predict a low risk of re-
currence, the same group carried out a second study, the 
PROLONG II study, with the aim to assess the time course 
of D-dimer and its relation with late recurrences in patients 
with normal D-dimer 1 month after anticoagulation suspen-
sion for a first episode of unprovoked VTE [12]. This study 
showed that when D-dimer becomes abnormal at the third 
month and remains abnormal afterward, the risk of re-
curren ce is h ig her t h an  in   patient s in wh o m D-dimer remain s 
normal at the third month and afterward (adjusted hazard 
ratio: 7.9; 95% confidence interval: 2.1-30).
  Two randomized controlled studies have evaluated the 
role of residual vein thrombosis to predict the risk of re-
current VTE [15, 16]. In the first study, patients with a 
first episode of DVT were managed according to ultrasound 
findings after an initial course of oral anticoagulant 
treatment. Patients with evidence of residual vein thrombosis 
were randomized to either stop or continue anticoagulants 
for 9 additional months, whereas patients without residual 
vein thrombosis treatment was stopped [15]. Residual throm-
bosis was detected in 69.8% of patients; recurrent events 
occurred in 27.2% of those who discontinued (15.2% per-
son-years) and 19.3% of those who continued oral anti-
coagulant treatment (10.1% person-years). The relative ad-
j u s t e d  h a z a r d  r a t i o  w a s  1 . 5 8  ( 9 5 %  c o n f i d e n c e  i n t e r v a l  
0.85-2.93). Of the 30.2% patients without residual thrombo-
sis, only 1.3% (0.63% person-years) had a recurrence. In 
the second study, 538 patients with a first episode of acute 
proximal DVT at completion of an uneventful 3-month peri-
od of anticoagulation were randomly assigned to fixed-dura-
tion anticoagulation (no further anticoagulation for secon-
dary thrombosis and an extra 3 months for unprovoked 
thrombosis) or flexible-duration, ultrasonography-guided 
anticoagulation (no further anticoagulation in patients with 
recanalized veins and continued anticoagulation in all other 
patients for up to 9 months for secondary DVT and up to 
21 months for unprovoked thrombosis) [16]. Overall, 17.2% 
of the patients allocated to fixed- duration anticoagulation 
and 11.9% of the patients allocated to flexible-duration anti-
coagulation developed recurrent VTE (adjusted hazard ratio, 
0.64; 95% confidence interval 0.39-0.99). For patients with 
unprovoked DVT, the adjusted hazard ratio was 0.61 (95% 
confidence interval 0.36-1.02) and 0.81 (95% confidence in-
terval 0.32-2.06) for those with secondary DVT.
NEW ANTICOAGULANTS FOR THE TREATMENT OF 
VENOUS THROMBOEMBOLISM
  The approach to the development of new anticoagulants 
as alternatives to heparins and vitamin K antagonists has 
been guided by the requirement for convenient admin-
istration with predictable pharmacokinetics, pharmacody-
namics and a wide therapeutic window that would permit 
fixed dosing without requiring coagulation monitoring. 
Research has in particular focussed on targeting thrombin 
(Factor IIa) and Factor Xa, which are common to both the Korean J Hematol 2010;45:8-13
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intrinsic and extrinsic coagulation pathways (Fig. 1). Throm-
bin inhibitors act to prevent fibrin formation, as well as 
inhibiting thrombin-mediated activation of Factors V, VIII, 
XI and XIII, and platelets. Inhibitors of Factor Xa act at 
an earlier stage in the cascade, they can inhibit both free 
and prothrombinase-bound Factor Xa and are also able to 
inhibit clot-associated Factor Xa, thus preventing clot-asso-
ciated Factor Xa from activating prothrombin and thereby 
contributing to the procoagulant activity of thrombi and 
therefore to the propagation of the thrombus [17].
1. Direct thrombin inhibitors
  Dabigatran etexilate is an univalent direct thrombin in-
hibitor that binds exclusively to the active site of thrombin 
with the advantage, in comparison with heparins, to in-
activate fibrin-bound thrombin. Moreover, dabigatran etex-
ilate is a reversible direct thrombin inhibitor, which dis-
sociates relatively quickly from thrombin, leaving a small 
amount of free, enzymatically active thrombin available for 
control of haemostasis. Dabigatran etexilate, is the prodrug 
of dabigatran, is rapidly absorbed from the gastro-intestinal 
tract and has a rapid onset of the anticoagulant activity, 
with  plasma levels peak at 2 hours [18]. The half-life ranges 
between 12 and 17 hours [18]. Dabigatran produces a predict-
able anticoagulant effect, requires no coagulation monitoring 
and can be given once daily. It prolongs the activated partial 
thromboplastin time, but its effect is not dose-linear and 
it is not suitable for a precise quantification of the anti-
coagulant effect. At least 80% of dabigatran is excreted un-
changed via the kidneys; therefore, the drug is contra-
indicated in patients with severe renal failure, with a crea-
tinine clearance less than 30 mL/min [18]. Dabigatran etex-
ilate has been already licensed in the European Union and 
in Canada for the prevention of VTE in patients undergoing 
hip- and knee-replacement surgery, with a recommended 
dose of 220 mg once daily for all patients but those with 
moderate renal insufficiency (creatinine clearence between 
30 and 50 mL/min) and the elderly (aged 75 or more), for 
whom the recommended dose is 150 mg once daily [19]. 
A dose reduction is also recommended for patients on amio-
darone treatment [19]. 
  Dabigatran etexilate is currently undergoing a large phase 
III program for the evaluation of its efficacy and safety in 
the acute treatment end in the secondary prevention of VTE. 
The RE-COVER trial evaluated dabigatran for 6 month treat-
ment of acute symptomatic VTE, while the RE-MEDY and 
the RE-SONATE trials are recruiting patients who have been 
successfully treated with standard doses of an approved anti-
coagulant for three to six months or who have completed 
6 to 18 months of treatment with vitamin K antagonist for 
confirmed acute symptomatic VTE, respectively. The RE- 
COVER study was published at the end of 2009 [20]. Patients 
with acute VTE, DVT and/or PE, who were initially treated 
with parenteral anticoagulants, were randomized to receive 
dabigatran etexilate, administered at a dose of 150 mg twice 
daily, or dose adjusted warfarin (international normalized 
ratio of 2.0 to 3.0). The primary outcome of the study was 
the 6-month incidence of recurrent symptomatic, objectively 
confirmed VTE and related deaths. Thirty of the 1,274 (2.4%) 
dabigatran patients, as compared with 27 of the 1,265 (2.1%) 
warfarin patients, had recurrent VTE. The difference in risk 
was 0.4 percentage points (95% confidence interval, −0.8- 
1.5). The hazard ratio with dabigatran was 1.10 (95% con-
fidence interval, 0.65-1.84). Major bleeding episodes oc-
curred in 20 (1.6%) dabigatran patients and in 24 (1.9%) 
warfarin patients (hazard ratio with dabigatran, 0.82; 95% 
CI, 0.45-1.48), and episodes of any bleeding were observed 
in 205 (16.1%) dabigatran patients and in 277 (21.9%) warfar-
in patients (hazard ratio with dabigatran, 0.71; 95% con-
fidence interval, 0.59-0.85).
2. Direct factor Xa inhibitors
  Rivaroxaban is the first of this new class of drugs. It is 
a potent and selective oral Factor Xa inhibitor with a partic-
ular chemical structure in its active-site binding region that 
plays a role in the oral absorption of the drug, with a relatively 
high bioavailabity (nearly 80%) [21]. Plasma levels of the 
drug peak after 3 to 4 hours, with a mean half-life ranging 
from 5 to 9 hours in young individuals, and from 11 to 
13 hours in the elderly [22]. The main route of excretion 
is renal, but the drug is also expelled via the faecal/biliar 
route [23]. Rivaroxaban can be administered at a fixed dose 
in any patient and does not need laboratory monitoring. 
Also rivaroxaban has been licensed in the European Union 
and in Canada for the prevention of VTE in patients under-
going hip- and knee-replacement surgery, with a recom-
mended dose of 10 mg once daily [24]. 
  Two phase II, dose-finding studies compared rivaroxaban 
administered at total daily doses ranging from 20 mg to 
60 mg with standard therapy with LMWH followed by oral 
vitamin K antagonists [25, 26]. Based on the positive results 
of these studies, the following doses were selected for further 
investigation in the three phase III clinical trials aimed to 
assess the acute phase and the long term treatment of DVT 
and PE (the Einstein studies): 15 mg bid for 3 weeks followed 
by 20 mg qd in the ongoing Einstein DVT and Einstein 
PE studies, in which patients with objectively confirmed, 
symptomatic DVT or PE are randomized to treatment with 
rivaroxaban alone or with LMWH and vitamin K antagonists 
for a total period of 3 to 12 months, and 20 mg qd in the 
Einstein Extension study, in which patients who had com-
pleted 6 to 12 months of anticoagulant treatment with either 
vitamin K antagonists or rivaroxaban (if also enrolled in 
the acute phase studies) after an acute episode of VTE were 
randomized to rivaroxaban or placebo for additional 6 to 
12 months. The Einstein Extension study is already com-
pleted, and the results have been presented at the American 
Society of Hematology meeting in December 2009 [27]. In 
this randomised, double blind, placebo-controlled study, the 
primary efficacy outcome was the recurrence of symptomatic 
VTE and the principal safety outcome was the occurrence 
of major bleeding. During treatment, symptomatic recurrent 
VTE events occurred in 7.1% patients treated with placebo 
and in 1.3% patients treated with rivaroxaban (hazard ratio, Korean J Hematol 2010;45:8-13.
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0.18; 95% confindence interval, 0.09-0.39). After stopping 
the study medication, 1.0% symptomatic recurrent VTE 
events occurred in both groups during the one month ob-
servational period of follow up. No major bleeding events 
were documented in the group of patients treated with place-
bo, 4 (0.7%) major bleeding events occurred in the rivarox-
aban group (P=0.106). None of these bleeding events were 
fatal or occurred in a critical site. Clinically relevant non-ma-
jor bleeding occurred in 1.2% and in 5.4% patients random-
ized to placebo and rivaroxaban, respectively. Two (0.3%) 
patients in the placebo group and 1 (0.2%) patient in the 
rivaroxaban group died.
  Apixaban is an oral active Factor Xa inhibitor derived 
from razaxaban (an aminobenzisoxazole that binds to the 
active site of Factor Xa with high affinity), with superior 
pharmacological proprieties [17]. It is a small molecule able 
to inhibit in a selective and reversible manner the active 
site of both free and prothrombinase-bound Factor Xa. 
Preclinical studies demonstrate that apixaban has an oral 
bioavailability of more than 50%: its plasma peak is achieved 
in about 3 h and its half-life is about 12 h [28]. The drug 
is absorbed in the gastrointestinal tract, is metabolised in 
the liver by cythocrome-dependent and -independent mech-
anisms and it is eliminated through both the renal and the 
faecal routes [29].
  Apixaban has been assessed for the treatment of DVT 
in a dose finding study (Botticelli DVT study) [30]. Patients 
were randomised to receive apixaban 5 mg bid, 10 mg bid, 
20 mg od or LMWH vitamin K antagonists. The primary 
efficacy outcome, defined as the composite of symptomatic 
recurrent VTE and asymptomatic deterioration in the throm-
botic burden as assessed by repeat bilateral compression ultra-
sonography and perfusion lung scan, occurred in 4.7% of 
patients treated with apixaban and in 4.2% of LMWH/vita-
min K antagonists treated patients. No dose effect was ob-
served across apixaban doses. The principal safety outcome, 
defined as the composite of major and clinically relevant 
non-major  bleeding, occurred in 7.3% of the apixaban treated 
patients and in 7.9% of LMWH/vitamin K antagonists treated 
patients. On the basis of this study, phase III studies 
(AMPLIFY and AMPLIFY extension), testing apixaban at 
the doses of 10 mg and 5 mg twice daily, are now undergoing.
Studies assessing the efficacy and safety of other factor Xa 
inhibitors, such as edoxaban, are also underway.
CONCLUSIONS
  The current management of VTE is largely based on the 
use of anticoagulant drugs, both parenteral drugs such as 
UFH, LMWH or fondaparinux for the treatment of the acute 
phase and oral drugs such as the vitamin K antagonists for 
the long term secondary prevention. All these drugs have 
been proven to be highly effective in preventing thrombus 
propagation, embolization, and recurrence. For the manage-
ment of the acute phase of the disease, LMWH has largely 
replaced UFH thus contributing to simplify the management 
of VTE, and now a large proportion of patients with DVT 
do not need to be hospitalized and can be entirely treated 
as outpatients. For the long term secondary prevention, vita-
min K antagonists remain the only choice for clinicians, 
and their clear benefits in terms of efficacy need to be periodi-
cally balanced in each patient against their risks in terms 
of safety and their inconvenient management. In a very 
near future, the armamentarium of clinicians involved in 
the prevention and treatment of thromboembolic disorders 
could become much larger. After the positive results of the 
first clinical trials, new direct thrombin inhibitors and direct 
Factor Xa inhibitors that are administered orally are closely 
approaching the market. With predictable anticoagulant re-
sponses and low potential for food-drug and drug-drug inter-
actions, these new agents can be given in fixed doses without 
coagulation monitoring. These properties and the oral admin-
istration render these compounds more convenient than both 
vitamin K antagonists and LMWH. Based on design of the 
phase III clinical trials, we can speculate that some of these 
compounds will challenge the vitamin K antagonists for the 
long term secondary prevention of VTE, and that other will 
also challenge the parenteral drugs for the acute phase man-
agement, as they are tested as a stand-alone treatment for 
both DVT and PE. Thus, patients with VTE could be treated 
with a single oral agent right after the objective diagnosis 
of the disease. Specific areas of particular interest for these 
new agents include the treatment of patients with cancer 
and VTE, for whom long term treatment with LMWH is 
currently recommended and for whom an oral agent with 
a low propensity for drug-drug interactions could represent 
the ideal therapy, and of course the long term treatment 
of patients with unprovoked VTE, where the complex bal-
ance between benefits and risks of the currently available 
drugs could be simplified with the use of more practical 
agents.
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